The tumour growth kinetics following vaccination with TS.VP60, especially with the significantly delayed emergence of recurrent tumours, did indicate that targeting both topIIα and survivin simultaneously altered the capacity for tumours to evolve and escape. This evidence concerns the gene BIRC5 and neoplasm.